In a research report issued yesterday, Cantor analyst Elemer Piros reiterated a Buy rating on shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR), with a price …
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced that it has dosed the first patient in the multiple ascending dose (MAD) portion of its ongoing Phase 1/2 …
This morning, Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced the initiation of its Phase II trial for its pipeline drug ARC-AAT, a RNAi based investigational …
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced that it initiated a Phase 2 clinical study of ARC-AAT, an investigational RNAi-based medicine for the treatment of liver …
Arrowhead on the cutting edge of providing curative hepatitis B, says Cantor analyst
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced financial results for its fiscal 2016 third quarter ended June 30, 2016. Fiscal 2016 Third Quarter and Recent …
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced that it initiated a Phase 1/2 study of ARC-521, the company’s second RNAi-based investigational medicine for the treatment of …
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) announced financial results for its fiscal 2016 second quarter ended March 31, 2016. The company is hosting a conference …
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR), recently filed a regulatory submission in New Zealand to begin a Phase 1/2 clinical trial of ARC-521, its RNAi-based therapeutic …
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) presented a poster on ARC-HIF2, its preclinical development program targeting HIF2-α for the treatment of renal cell carcinoma (RCC), at …
